Entelos Announces Agreement with GlaxoSmithKline


 
TIDMENTL




  Entelos, Inc. (LSE: ENTL), a leader in predictive disease simulation for pharmaceutical, health-care and consumer products applications, announced today that GlaxoSmithKline ("GSK") has signed an agreement with Entelos to conduct in silico research using the Entelos� Hematopoeisis PhysioLab� platform.




  The Entelos Hematopoeisis PhysioLab platform is a powerful and innovative computer model that can simulate the complex biology of anemic patients and large "virtual patient populations" to predict responses to drugs. It has already been used successfully with other pharmaceutical partners to assess the safety and efficacy of biologics, find the best doses for specific patient types, and optimize complicated, adaptive clinical trial designs to better position products in the highly competitive market for anti-anemia drugs.




  "We are pleased to continue working with GSK," commented James Karis, President and CEO of Entelos. "This is the third in a series of projects we have conducted across multiple therapeutic areas for GSK over several years. We look forward to delivering results that can help accelerate compound development at GSK."




  For further information please contact:


 
Entelos, Inc. 
Joy Lowe                            Tel: +1 650 572 5400 
KBC Peel Hunt, Ltd (Nominated 
Advisor and Broker) 
Capel Irwin/David Anderson          Tel +44 (0) 20 4718 8900 
Buchanan Communications 
Lisa Baderoon / Mary-Jane Johnson   Tel +44 (0) 20 7466 5000




  About Entelos




  Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, "virtual human" technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.

Entelos Regs (LSE:ENTL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024